AAAAAA

   
Results: 1-13 |
Results: 13
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg (TM) CMA-676)
Authors: Petti, MC Pinazzi, MB Diverio, D Romano, A Petrucci, MT De Santis, S Meloni, G Tafuri, A Mandelli, F Lo Coco, F
Citation: Mc. Petti et al., Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg (TM) CMA-676), BR J HAEM, 115(1), 2001, pp. 63-65
Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients
Authors: Casassus, P Gibson, J Joshua, DE Matthews, J Diaz, JC Gertz, MA Kyle, R Leong, T Oken, MM Fritz, E Ludwig, H Corrado, C Lastiri, F Peest, D Grosbois, B Vela-Ojeda, J Avvisati, G Mandelli, F Petrucci, MT Capnist, G Child, JA Drayson, MT Dunn, J MacLennan, I Mellstedt, H Osterborg, A Rodjer, S Turesson, I Westin, J Bergsagel, D Browman, GP Shustik, C Zee, B Hjorth, M Holmberg, E Rodjer, S Turesson, I Westin, J Alison, R Clarke, M Elphinstone, P Evans, V Gray, R Hicks, C James, S MacKinnon, L Peto, R Richards, S Wheatley, K Blade, J Fontanillas, M San Miguel, J Aitchison, R Newland, AC Cunningham, D Malpas, J Powles, RL Montuoro, A Jacobson, J Salmon, S
Citation: P. Casassus et al., Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients, BR J HAEM, 113(4), 2001, pp. 1020-1034
Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia
Authors: Ricciardi, MR Petrucci, MT Gregorj, C Ariola, C Lemoli, RM Fogli, M Mauro, FR Cerretti, R Foa, R Mandelli, F Tafuri, A
Citation: Mr. Ricciardi et al., Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia, BR J HAEM, 113(2), 2001, pp. 391-399
Thrombopoietin, interleukin-11, and early-acting megakaryocyte growth factors in human myeloid leukemia cells
Authors: Petrucci, MT Riccardi, MR Gregorj, C Ariola, C Mazzola, F Fogli, M Lemoli, RM Tafuri, A
Citation: Mt. Petrucci et al., Thrombopoietin, interleukin-11, and early-acting megakaryocyte growth factors in human myeloid leukemia cells, LEUK LYMPH, 40(1-2), 2000, pp. 179-190
Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patients
Authors: Petrucci, MT La Verde, G Ribersani, M Avvisati, G Mandelli, F
Citation: Mt. Petrucci et al., Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patients, LEUK LYMPH, 39(1-2), 2000, pp. 131-138
Isolated granulocytic sarcoma of the skin in an elderly patient: good response to treatment with local radiotherapy and low-dose methotrexate
Authors: Pulsoni, A Falcucci, P Anghel, G Ribersani, M Petrucci, MT Pescarmona, E Muscardin, L
Citation: A. Pulsoni et al., Isolated granulocytic sarcoma of the skin in an elderly patient: good response to treatment with local radiotherapy and low-dose methotrexate, J EUR A D V, 14(3), 2000, pp. 216-218
Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients
Authors: Palumbo, A Triolo, S Baldini, L Callea, V Capaldi, A De Stefano, V Grasso, M Liberati, M Lotesoriere, C Marceno, R Marmont, F Musto, P Petrucci, MT Spriano, M Pileri, A Boccadoro, M
Citation: A. Palumbo et al., Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients, HAEMATOLOG, 85(5), 2000, pp. 508-513
Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian multicenter study
Authors: Tribalto, M Amadori, S Cudillo, L Caravita, T Del Poeta, G Meloni, G Avvisati, G Petrucci, MT Pulsoni, A Leone, G Sica, S Martelli, M Tabilio, A Fioritoni, G Majolino, I Mandelli, F
Citation: M. Tribalto et al., Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian multicenter study, HAEMATOLOG, 85(1), 2000, pp. 52-58
High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study
Authors: Meloni, G Capria, S Trasarti, S Ferrazza, G Micozzi, A Petrucci, MT Simone, F Trisolini, SM Mandelli, F
Citation: G. Meloni et al., High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study, BONE MAR TR, 26(10), 2000, pp. 1045-1049
Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1
Authors: Petrucci, MT Ricciardi, MR Ariola, C Gregorj, C Ribersani, M Savino, R Ciliberto, G Tafuri, A
Citation: Mt. Petrucci et al., Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1, ANN HEMATOL, 78(1), 1999, pp. 13-18
Beneficial effect of highly active antiretroviral therapy (HAART) in reducing both HIV viral load and monoclonal gammopathy
Authors: Cauda, R Lucia, MB Marasca, G Rutella, S Petrucci, MT La Verde, G Gastaldi, R
Citation: R. Cauda et al., Beneficial effect of highly active antiretroviral therapy (HAART) in reducing both HIV viral load and monoclonal gammopathy, EUR J HAEMA, 63(2), 1999, pp. 134-135
Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells
Authors: Tafuri, A Lemoli, RM Petrucci, MT Ricciardi, MR Fogli, M Bonsi, L Ariola, C Strippoli, P Gregorj, C Petti, MC Tura, S Mandelli, F Bagnara, GP
Citation: A. Tafuri et al., Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells, EXP HEMATOL, 27(8), 1999, pp. 1255-1263
Combination chemotherapy versus melphalan plus prednisone as treatment formultiple myeloma: An overview of 6,633 patients from 27 randomized trials
Authors: Pasquali, S Maqueo, JD Vela, J Kyle, RA Leong, T Fritz, E Suciu, S Palva, IP Oivanen, T Corrado, C Lastiri, FJ Peest, D Kildahl-Andersen, O Maniatis, A Alison, R Clarke, M Evans, V Gray, R Greaves, E Hall, E Hicks, C James, S Peto, R Richards, S Sinclair, D Tooth, A Wheatley, K Avvisati, G Boccadoro, M Bugliosi, R Mandelli, F Petrucci, MT Pileri, A Tribalto, M Alexanian, R Delasalle, KB Child, J Dunn, J MacLennan, I Milligan, D Mellstedt, H Osterborg, A Hjorth, M Holmberg, E Rodjer, S Westin, J Kamiya, O Shimizu, K Bergsagel, DE Shustik, C Hippe, E Kjaersgaard, E Turesson, I Westin, J Riccardi, A Ucci, G Blade, J Fontanillas, M De Rosa, L Montuoro, A Bartolucci, AA Omura, GA Stagg, M Salmon, S Tangen, C Jacobs, P Wood, L Levy, LM
Citation: S. Pasquali et al., Combination chemotherapy versus melphalan plus prednisone as treatment formultiple myeloma: An overview of 6,633 patients from 27 randomized trials, J CL ONCOL, 16(12), 1998, pp. 3832-3842
Risultati: 1-13 |